LATEST NEWS
December 21, 2018 | Company Announcements
Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox VaccineNovember 13, 2018 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramNovember 09, 2018 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2018 November 02, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic CancersNovember 01, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Trial of BN-Brachyury for the Treatment of Chordoma November 01, 2018 | Company Announcements
Henrik Juuel Joins Bavarian Nordic as Chief Financial OfficerSeptember 18, 2018 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder CancerAugust 16, 2018 | Company Announcements
Bavarian Nordic Announces First Half 2018 Results August 09, 2018 | Company Announcements
Bavarian Nordic Granted EUR 30 Million Loan from The European Investment BankAugust 08, 2018 | Company Announcements
Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine